Evaluation of the biocompatibility of calcium phosphate cement/PLGA microparticle composites

  1. Dennis P. Link1,
  2. Juliette van den Dolder1,
  3. Jeroen J. J. P. van den Beucken1,
  4. Vincent M. Cuijpers1,
  5. Joop G. C. Wolke1,
  6. Antonios G. Mikos2,
  7. John A. Jansen1,*

Article first published online: 15 JAN 2008

DOI: 10.1002/jbm.a.31831

Issue

Journal of Biomedical Materials Research Part A

Journal of Biomedical Materials Research Part A

Volume 87A, Issue 3, pages 760–769, 1 December 2008

Additional Information

How to Cite

Link, D. P., van den Dolder, J., van den Beucken, J. J. J. P., Cuijpers, V. M., Wolke, J. G. C., Mikos, A. G. and Jansen, J. A. (2008), Evaluation of the biocompatibility of calcium phosphate cement/PLGA microparticle composites. J. Biomed. Mater. Res., 87A: 760–769. doi: 10.1002/jbm.a.31831

Author Information

  1. 1

    Department of Periodontology and Biomaterials, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands

  2. 2

    Department of Bioengineering, Rice University, Houston, Texas

*Department of Periodontology and Biomaterials, PB 309, Radboud University, Nijmegen Medical Center, PO Box 9101, 6500 HB Nijmegen, The Netherlands

Publication History

  1. Issue published online: 24 OCT 2008
  2. Article first published online: 15 JAN 2008
  3. Manuscript Accepted: 18 OCT 2007
  4. Manuscript Revised: 3 SEP 2007
  5. Manuscript Received: 16 APR 2007

Funded by

  • Ministry of Economic Affairs. Grant Number: NGT6205

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (518K)

Keywords:

  • CaP/PLGA cement;
  • biocompatibility;
  • interconnectivity

Abstract

In this study, the biocompatibility of a calcium phosphate (CaP) cement incorporating poly (D,L-lactic-co-glycolic acid) (PLGA) microparticles was evaluated in a subcutaneous implantation model in rats. Short-term biocompatibility was assessed using pure CaP discs and CaP discs incorporating PLGA microparticles (20% w/w) with and without preincubation in water. Long-term biocompatibility was assessed using CaP discs incorporating varying amounts (5, 10, or 20% w/w) and diameter sizes (small, 0–50 μm; medium, 51–100 μm, or large, 101–200 μm) of PLGA microparticles. The short-term biocompatibility results showed a mild tissue response for all implant formulations, irrespective of disc preincubation, during the early implantation periods up to 12 days. Quantitative histological evaluation revealed that the different implant formulations induced the formation of similar fibrous tissue capsules and interfaces. The results concerning long-term biocompatibility showed that all implants were surrounded by a thin connective tissue capsule (<10 layers of fibroblasts). Additionally, no significant differences in capsule and interface scores were observed between the different implant formulations. The implants containing 20% PLGA with medium- and large-sized microparticles showed fibrous tissue ingrowth throughout the implants, indicating PLGA degradation and interconnectivity of the pores. The results demonstrate that CaP/PLGA composites evoke a minimal inflammatory response. The implants containing 20% PLGA with medium- and large-sized microparticles showed fibrous tissue ingrowth after 12- and 24-weeks indicating PLGA degradation and interconnectivity of the pores. Therefore, CaP/PLGA composites can be regarded as biocompatible biomaterials with potential for bone tissue engineering and advantageous possibilities of the microparticles regarding material porosity. © 2008 Wiley Periodicals, Inc. J Biomed Mater Res, 2008

View Full Article (HTML) Get PDF (518K)